UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000029590 |
|---|---|
| Receipt number | R000033806 |
| Scientific Title | An accompanying research for the Phase II study of nivolumab + bevacizumab + paclitaxel in patients with HER2-negative metastatic breast cancer:WJOG9917B(WJOG9917BTR) |
| Date of disclosure of the study information | 2017/10/17 |
| Last modified on | 2023/08/08 14:15:52 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2017/10/17 11:15:46 | ||
| 2 | Update | 2017/10/18 12:56:08 | Organization Organization Organization Category of Funding Organization |
|
| 3 | Update | 2017/12/04 10:11:09 | Organization Organization Organization Category of Funding Organization Nationality of Funding Organization |
|
| 4 | Update | 2017/12/04 10:12:25 | Institutions |
|
| 5 | Update | 2018/02/05 14:57:58 | Recruitment status |
|
| 6 | Update | 2019/01/29 16:10:44 | Recruitment status |
|
| 7 | Update | 2023/01/10 09:51:37 | Recruitment status Date of IRB Last follow-up date |
|
| 8 | Update | 2023/08/08 12:07:24 | Date analysis concluded |
|
| 9 | Update | 2023/08/08 14:15:52 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Organization Organization Division name Division name Zip code Address Address TEL Last name of contact person Last name of contact person Zip code Address Nationality of Funding Organization Organization Organization Address Address Tel |
